['hepatitis c']
['abt-493', 'abt-530']

        Inclusion Criteria:

          1. Participant is male or female 18 years of age or older

          2. Participant has received at least one dose of an ABT-493- and/or ABT- 530 containing
             regimen in a prior AbbVie hepatitis C virus (HCV) Phase 2 or 3 study

          3. The interval between the last dose of the AbbVie direct-acting antiviral agent (DAA)
             therapy from the previous clinical study and enrollment in Study M13-576 must be no
             longer than 2 years for subjects who have not been retreated. Participants who have
             been treated with a commercially available anti-HCV treatment may be enrolled greater
             than 2 years after the last dose of the AbbVie DAA therapy from the previous clinical
             study.

          4. Participant must voluntarily sign and date the informed consent form approved by an
             Independent Review Board or Ethics Committee prior to the initiation of any
             study-specific procedures.

          5. Participant completed the post-treatment period of an eligible prior study.

        Exclusion Criteria:

          1. The investigator considers the participant unsuitable for the study for any reasons
             (e.g., failure to comply with study procedures in the prior AbbVie clinical study).

          2. Receipt of any investigational HCV antiviral treatment after receiving ABT-493 and/or
             ABT-530 in the prior study.

          3. Participants who experienced non-virologic treatment failure due to premature
             discontinuation of study drug in prior study of ABT-493/ABT-530.

          4. Participation in AbbVie's Study M15-942 protocol for re-treatment for virologic
             failure in the prior Phase 2 or 3 study.
      